Brain vasopressin levels in Down Syndrome and Alzheimer's disease

Brain Research

Volumn 806, Issue 1, 1998, Pages 55-59

  Labudova, Olga ^a   Fang Kircher, Susanne ^b   Cairns, Nigel ^c   Moenkemann, Heike ^d   Yeghiazaryan, Kristina ^d   Lubec, Gert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Institute of Medical Chemistry   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer's Disease; Down Syndrome; Subtractive hybridization; Vasopressin

Indexed keywords

MESSENGER RNA; VASOPRESSIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DNA HYBRIDIZATION; DOWN SYNDROME; FETUS; GENE ISOLATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEQUENCE HOMOLOGY;

AGED; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARGININE VASOPRESSIN; BASE SEQUENCE; BRAIN; DOWN SYNDROME; FEMALE; FETUS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NUCLEIC ACID HYBRIDIZATION; TISSUE DISTRIBUTION;

EID: 0032556068     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00730-6     Document Type: Article

References (30)

1. Baran H., Cairns N., Lubec B., Lubec G. Increased kynurenic acid levels and decreased brain kynurenine aminotransferases in patients with Down Syndrome. Life Sci. 58:1996;1891-1899.
2. Beardwell C.G. Radioimmunoassay of arginine vasopressin in human plasma. J. Clin. Endocrinol. 33:1971;254-260.
3. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
4. R. Bujis, M.L.H. Hermes, A. Kalsbeek, T. van der Woude, J.J. van Heerikhuize, Vasopressin distribution, origin and functions in the central nervous system, in: S. Jard, R. Jamison (Eds.), Vasopressin, Libbey, Paris, 1991, 149-158.
5. de Wied D., Diamant M., Fodor M. Central nervous effects of neurohypophyseal hormones and related peptides. Front. Neuroendocrinol. 14:1993;251-302.
6. de Wied D. The influence of the posterior and intermediate lobe of the pituitary and pituitary peptides on the maintenance of a conditioned avoidance response in rats. Int. J. Neuropharmacol. 4:1965;157-167.
7. Engelmann M., Wotjak C.T., Neumann I., Ludwig M., Landgraf R. Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci. Biobehav. Rev. 20:1996;341-358.
8. C.J. Epstein, Down Syndrome (Trisomy 21), in: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.), The Metabolic and Molecular Basis of Inherited Disease, McGraw-Hill, New York, 1992, pp. 749-794.
9. Godridge H., Reynolds G.P., Czudek C., Calcutt N.A., Benton M. Alzheimer-like neurotransmitter deficits in adult Down Syndrome brain tissue. J. Neurol. Neurosurg. Psychiatry. 50:1980;775-778.
10. Jenkins J.S., Ang V.T.Y., Hawthorn J., Rossor M.N., Iversen L.L. Vasopressin, oxytocin and neurophysins in the human brain and spinal cord. Brain Res. 291:1984;111-117.
11. Kish F., Karlinski H., Becker L., Gilbert J., Rebbetoi M., Chang L.J., diStefano L., Hornykiewicz O. Down Syndrome individuals begin life with normal levels of brain cholinergic markers. J. Neurochem. 52:1989;1183-1187.
12. Korting C., Van Zwieten E.J., Boer G.J., Ravid R., Swaab D.F. Increase in vasopressin binding sites in the human choroid plexus in Alzheimer's disease. Brain Res. 706:1996;151-154.
13. Labudova O., Lubec G. cAMP upregulates the transposable element mys-1: a possible link between signaling and mobile DNA. Life Sci. 62:1998;431-437.
14. Lucassen P.J., Salehi A., Pool C.W., Gonatas N.K., Swaab D.F. Activation of vasopressin neurons in Alzheimer's disease. J. Neuroendocrinol. 6:1994;673-679.
15. Mengod G., Goudsmit E., Probst A., Palacios J.M. In situ hybridization histochemistry in the human hypothalamus. Progr. Brain Res. 93:1992;45-55.
16. Mirra S.S., Heyman A., McKeel D., Sumi S., Crain B.J. The consortium to establish a registry for Alzheimer's disease (CERAD): II. Standardisation of the neuropathological assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
17. Rehbein M., Hillers M., Mohr E., Ivell R., Morley S., Schmale H., Richter D. The neurohypophyseal hormones vasopressin and oxytocin. Precursor structure, synthesis and regulation. Biol. Chem. Hoppe-Seyler. 367:1986;695-704.
18. Risser D., You Z.B., Cairns N., Herrera Marschitz M., Seidl R., Schneider C., Terenius L., Lubec G. Endogenous opioids in frontal cortex of patients with Down Syndrome. Neurosci. Lett. 203:1996;111-114.
19. Risser D., Lubec G., Cairns N., Herrera-Marschitz M. Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down Syndrome. Life Sci. 60:1997;1231-1237.
20. Roberson G.L. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J. Clin. Invest. 52:1973;2340-2352.
21. Rossor M.N., Iversen L.L., Hawthorn J., Ang V.T.Y., Jenkins J.S. Extrahypothalamic vasopressin in human brain. Brain Res. 214:1981;349-355.
22. Schmidt H.J., Schaum U., Pichotka J.P. The influence of mode and intensity of homogenization on the absolute value and stability of oxygen consumption of guinea pig liver homogenates. Z. Naturforsch. C. 32:1977;908-912.
23. Seidl R., Greber S., Schuller E., Bernert G., Cairns N., Lubec G. Evidence against increased oxidative DNA damage in Down Syndrome. Neurosci. Lett. 235:1997;137-140.
24. M.V. Sofroniew, in: A. Bjoerklund, T. Hoekfelt (Eds.), Handbook of Chemical Neuroanatomy, GABA and Neuropeptides in the CNS, Vol. 4, Elsevier, Amsterdam, 1985, pp. 93-165.
25. Tanaka M., Versteeg D.H.G., De Wied D. Regional effects of vasopressin on rat brain catecholamine metabolism. Neurosci. Lett. 4:1977;321-325.
26. Tierney M.C., Fisher R.H., Lewis A.J., Torzitto M.L., Snow W.G., Reid D.W., Nieuwstraaten P., Van Rooijen L.A.A., Derks H.J.G.M., Van Wijk R., Bischop A. The NINCDA-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer's disease. Neurology. 38:1988;359-364.
27. Van der Woude P.F., Goudsmit E., Wierda M., Purba J.S., Hofman M.A., Bogte H., Swaab D.F. No vasopressin cell loss in the human hypothalamus in aging and Alzheimer's disease. Neurobiol. Aging. 16:1995;11-18.
28. Van Zwieten E.J., Ravid R., Hoogendijjk W., Swaab D.F. Stable vasopressin innervation in the degenerating human locus coeruleus in Alzheimer's disease. Brain Res. 649:1994;329-333.
29. Van Zwieten E.J., Ravid R., Swaab D.F. Differential vasopressin and oxytocin innervation of the human parabrachial nucleus: no changes in Alzheimer's disease. Brain Res. 711:1996;146-152.
30. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological change and dementia of Alzheimer's disease in Down Syndrome. Ann. Neurol. 17:1985;278-282.